Raymond James Biotech Innovation Symposium: Tectonic Therapeutic develops biologics against GPCR targets - and is making headway on an unmet need for pulmonary hypertension in heart failure patients

Apr 14
1 min read

CEO Alise Reicin walks us through recent data and guides for what is next in this patient population. Plus, an upcoming healthily volunteer readout for a HHT program and how it might translate to patients in future trials.

https://vimeo.com/1183108122?share=copy&fl=sv&fe=ci

Coverage brought to you by

Recent Posts

See All

Epicrispr Biotechnologies closed a $90M series C on Tuesday to advance its epigenetic therapy toward pivotal studies in facioscapulohumeral muscular dystrophy (FSHD)

LifeMine Therapeutics announced a $263M raise today to help accelerate the development of its novel calcineurin activation inhibitor that aims to radically change the profile of organ transplants

From NYSE: Noetik has been building a large database from patient tumor samples to use AI to help understand which patients are more likely to respond to medicines in the future

Raymond James Biotech Innovation Symposium: Tectonic Therapeutic develops biologics against GPCR targets - and is making headway on an unmet need for pulmonary hypertension in heart failure patients

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight